Evidence map›Paper›PMID 32128875›Full record

ArticleDiabetic medicine : a journal of the British Diabetic Association2020

Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care.

W Hinton, M Feher, N Munro, M Joy, S de Lusignan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetic medicine : a journal of the British Diabetic Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

W HintonNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
M FeherNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
N MunroDepartment of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.
M JoyNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
S de LusignanNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Funding

AstraZenecaAstraZeneca UK Limited
6 · The paper itself

Abstract

aimTo identify people in English primary care with equivalent cardiovascular risk to participants in the sodium-glucose co-transporter-2 inhibitor (SGLT-2i) cardiovascular outcome trials (CVOTs). A secondary objective was to report the usage of SGLT-2is.

methodsCross-sectional analysis of people registered with participating practices in the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network on the 31 December 2016. We derived: (1) proportions of the primary care population eligible for inclusion in each SGLT-2i CVOT (CANVAS, DECLARE, EMPA-REG and VERTIS); (2) characteristics of the eligible population compared with trial participants (demographics, disease duration and vascular risk); and (3) differences within the eligible population prescribed SGLT-2is.

resultsThe proportions of people with type 2 diabetes (N = 84 394) meeting the inclusion criteria for each CVOT were: DECLARE 27% [95% confidence interval (CI) 26.5-27.1]; CANVAS 17% (16.6-17.1); VERTIS 7% (7.1-7.4); and EMPA-REG 7% (6.5-6.8). Primary care populations fulfilling inclusion criteria were 5-8 years older than trial cohorts, and <10% with inclusion criteria of each trial were prescribed an SGLT-2i; a greater proportion were men, and of white ethnicity.

conclusionsThere was variation in proportions of the primary care type 2 diabetes population fulfilling inclusion criteria of SGLT-2i CVOTs. The more stringent the inclusion criteria, the lower the proportion identified in a primary care setting. Prescription rates for SGLT-2is were low in this national database, and there were demographic disparities in prescribing.

Indexed as

Clinical Trials as TopicEligibility DeterminationPrimary Health CareAdultAgedAged, 80 and overCardiovascular DiseasesDatabases, FactualDiabetes Mellitus, Type 2EnglandFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedPractice Patterns, Physicians'Sodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID32128875
PMCPMC7497070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.